
Joseph Pape
Examiner (ID: 18031, Phone: (571)272-6664 , Office: P/3612 )
| Most Active Art Unit | 3612 |
| Art Unit(s) | 2899, 3102, 3612 |
| Total Applications | 4170 |
| Issued Applications | 3665 |
| Pending Applications | 184 |
| Abandoned Applications | 378 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15209779
[patent_doc_number] => 20190367576
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => ACTIVATABLE INTERLEUKIN 12 POLYPEPTIDES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/438166
[patent_app_country] => US
[patent_app_date] => 2019-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27497
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 113
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438166
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/438166 | Activatable interleukin 12 polypeptides | Jun 10, 2019 | Issued |
Array
(
[id] => 15454455
[patent_doc_number] => 20200040052
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-06
[patent_title] => ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/438156
[patent_app_country] => US
[patent_app_date] => 2019-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33867
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 116
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16438156
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/438156 | Activatable interleukin-2 polypeptides | Jun 10, 2019 | Issued |
Array
(
[id] => 15209833
[patent_doc_number] => 20190367603
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-05
[patent_title] => Cancer Treatment by Blocking Host-Induced IL-1 in Combination with Radiotherapy
[patent_app_type] => utility
[patent_app_number] => 16/425595
[patent_app_country] => US
[patent_app_date] => 2019-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6426
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16425595
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/425595 | Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy | May 28, 2019 | Issued |
Array
(
[id] => 14993791
[patent_doc_number] => 20190315853
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => ANTIBODIES TO IL-15
[patent_app_type] => utility
[patent_app_number] => 16/421509
[patent_app_country] => US
[patent_app_date] => 2019-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20626
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16421509
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/421509 | Antibodies to IL-15 and uses thereof | May 23, 2019 | Issued |
Array
(
[id] => 15083543
[patent_doc_number] => 20190336582
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => Compositions and Methods for Modulating IL-10 Immunostimulatory and Anti-Inflammatory Properties
[patent_app_type] => utility
[patent_app_number] => 16/414223
[patent_app_country] => US
[patent_app_date] => 2019-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17516
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16414223
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/414223 | Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties | May 15, 2019 | Issued |
Array
(
[id] => 17007112
[patent_doc_number] => 20210238273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-05
[patent_title] => TREATMENT OF ATOPIC DERMATITIS
[patent_app_type] => utility
[patent_app_number] => 17/048865
[patent_app_country] => US
[patent_app_date] => 2019-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8787
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17048865
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/048865 | TREATMENT OF ATOPIC DERMATITIS | Apr 23, 2019 | Abandoned |
Array
(
[id] => 16749943
[patent_doc_number] => 20210101952
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-04-08
[patent_title] => Engineered Optimized Cytokine Compositions
[patent_app_type] => utility
[patent_app_number] => 17/046393
[patent_app_country] => US
[patent_app_date] => 2019-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8384
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046393
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/046393 | Engineered Optimized Cytokine Compositions | Apr 8, 2019 | Abandoned |
Array
(
[id] => 16598080
[patent_doc_number] => 20210024611
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => Advanced Avatar Dendritic Cells
[patent_app_type] => utility
[patent_app_number] => 17/041377
[patent_app_country] => US
[patent_app_date] => 2019-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9954
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17041377
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/041377 | Immunoglobulin complex comprising interleukin-15 | Apr 2, 2019 | Issued |
Array
(
[id] => 15527275
[patent_doc_number] => 20200055943
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-20
[patent_title] => REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR
[patent_app_type] => utility
[patent_app_number] => 16/362581
[patent_app_country] => US
[patent_app_date] => 2019-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19828
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362581
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/362581 | REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR | Mar 21, 2019 | Abandoned |
Array
(
[id] => 15145091
[patent_doc_number] => 20190351023
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-21
[patent_title] => USE OF LOW DOSE IL-2 FOR TREATING AUTOIMMUNE - RELATED OR INFLAMMATORY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/361902
[patent_app_country] => US
[patent_app_date] => 2019-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13553
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361902
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/361902 | Use of low dose IL-2 for treating autoimmune--related or inflammatory disorders | Mar 21, 2019 | Issued |
Array
(
[id] => 14808433
[patent_doc_number] => 20190270826
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-05
[patent_title] => ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/358894
[patent_app_country] => US
[patent_app_date] => 2019-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51288
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358894
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/358894 | ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF | Mar 19, 2019 | Abandoned |
Array
(
[id] => 15571583
[patent_doc_number] => 10576150
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-03-03
[patent_title] => Anti-IL-23 antibodies
[patent_app_type] => utility
[patent_app_number] => 16/358775
[patent_app_country] => US
[patent_app_date] => 2019-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 11
[patent_no_of_words] => 30704
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358775
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/358775 | Anti-IL-23 antibodies | Mar 19, 2019 | Issued |
Array
(
[id] => 16305348
[patent_doc_number] => 10774126
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-09-15
[patent_title] => Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
[patent_app_type] => utility
[patent_app_number] => 16/352003
[patent_app_country] => US
[patent_app_date] => 2019-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 14
[patent_no_of_words] => 15783
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352003
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/352003 | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases | Mar 12, 2019 | Issued |
Array
(
[id] => 14534521
[patent_doc_number] => 20190202882
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-04
[patent_title] => MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/352249
[patent_app_country] => US
[patent_app_date] => 2019-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15782
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352249
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/352249 | Nucleic acid encoding human IL-2 variant | Mar 12, 2019 | Issued |
Array
(
[id] => 17134842
[patent_doc_number] => 11136388
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-05
[patent_title] => Biomarkers for anti-IL4-IL13 bispecific antibodies
[patent_app_type] => utility
[patent_app_number] => 16/297419
[patent_app_country] => US
[patent_app_date] => 2019-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 22
[patent_no_of_words] => 17440
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 238
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16297419
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/297419 | Biomarkers for anti-IL4-IL13 bispecific antibodies | Mar 7, 2019 | Issued |
Array
(
[id] => 15753759
[patent_doc_number] => 10618975
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-04-14
[patent_title] => Antibody to Renalase
[patent_app_type] => utility
[patent_app_number] => 16/295084
[patent_app_country] => US
[patent_app_date] => 2019-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 67
[patent_figures_cnt] => 82
[patent_no_of_words] => 38932
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16295084
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/295084 | Antibody to Renalase | Mar 6, 2019 | Issued |
Array
(
[id] => 17073771
[patent_doc_number] => 11110150
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-07
[patent_title] => Complexes of IL-15 and IL-15Ralpha and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/291561
[patent_app_country] => US
[patent_app_date] => 2019-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 15
[patent_figures_cnt] => 26
[patent_no_of_words] => 48094
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291561
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/291561 | Complexes of IL-15 and IL-15Ralpha and uses thereof | Mar 3, 2019 | Issued |
Array
(
[id] => 16770916
[patent_doc_number] => 10982005
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-20
[patent_title] => Antibodies to bone marrow stromal antigen 1
[patent_app_type] => utility
[patent_app_number] => 16/286363
[patent_app_country] => US
[patent_app_date] => 2019-02-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 21
[patent_no_of_words] => 46035
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16286363
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/286363 | Antibodies to bone marrow stromal antigen 1 | Feb 25, 2019 | Issued |
Array
(
[id] => 15309081
[patent_doc_number] => 10519231
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-12-31
[patent_title] => Method for treating lupus by administering an anti-IL-12 antibody
[patent_app_type] => utility
[patent_app_number] => 16/284316
[patent_app_country] => US
[patent_app_date] => 2019-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 14
[patent_no_of_words] => 28691
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16284316
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/284316 | Method for treating lupus by administering an anti-IL-12 antibody | Feb 24, 2019 | Issued |
Array
(
[id] => 15408043
[patent_doc_number] => 20200024343
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-23
[patent_title] => COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
[patent_app_type] => utility
[patent_app_number] => 16/280878
[patent_app_country] => US
[patent_app_date] => 2019-02-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34011
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16280878
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/280878 | COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE | Feb 19, 2019 | Abandoned |